Table 3.
Statistical Comparison of Clinical Characteristics Between Cohorts
| Clinical Characteristic | HIV/HCV Coinfection (n = 20) | HCV Monoinfection (n = 20) | P |
|---|---|---|---|
| Sex | |||
| Male | 20 (100) | 14 (70) | .020a |
| Female | 0 (0) | 6 (30) | |
| Age, mean (SD), y | 41 (8) | 34 (10) | .026a |
| Ethnicity | |||
| White | 19 (95) | 17 (85) | .605 |
| Other | 1 (5) | 3 (14) | |
| Mode of HCV acquisition | |||
| IDU | 10 (50) | 1 (85) | .054 |
| Sexual | 8 (40) | 2 (10) | |
| Other | 2 (10) | 1 (5) | |
| Estimated duration of infection, wk | |||
| Median (IQR) | 15 (8–17) | 18 (13–23) | .095 |
| Mean (SD) | 14 (6) | 17 (6) | |
| Presentation of recent HCV | |||
| Acute clinical (symptomatic) | 11 (55) | 10 (50) | .137 |
| Acute clinical (ALT >400 IU/mL) | 7 (35) | 3 (15) | |
| Asymptomatic seroconversion | 2 (10) | 7 (35) | |
| HCV RNA | |||
| Median (IQR), log10 IU/L | 5.26 (3.59–6.26) | 4.62 (3.49–5.61) | .234 |
| <400 000 IU/mL | 11 (55) | 15 (75) | |
| >400 000 IU/mL | 9 (45) | 5 (25) | |
| ALT | |||
| Median (IQR), IU/L | 324 (115–729) | 164 (70–354) | .239 |
| <100 IU/L | 5 (24) | 6 (29) | |
| >100 IU/L | 16 (76) | 15 (71) | |
| HCV genotype | |||
| 1 | 14 (70) | 8 (40) | .100 |
| 2 | 1 (5) | 2 (10) | |
| 3 | 4 (20) | 9 (45) | |
| 4 | 1 (5) | 0 (0) | |
| Mixed | 0 (0) | 1 (5) | |
| IL-28B genotypeb rs8099917 | |||
| TT | 13 (65) | 10 (50) | .730 |
| GT | 5 (25) | 7 (35) | |
| GG | 1 (5) | 0 (0) | |
| IL-28B genotype rs12980275 | |||
| AA | 9 (45) | 9 (45) | 1.000 |
| GA | 9 (45) | 8 (40) | |
| GG | 1 (5) | 0 (0) | |
| IL-28B genotype rs12989860 | |||
| CC | 10 (50) | 7 (35) | 1.000 |
| CT | 7 (35) | 3 (15) | |
| TT | 1 (5) | 2 (10) | |
Abbreviations: ALT, alanine aminotransferase; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, injection drug use; IL-28B, interleukin 28 B; IQR, interquartile range; SD, standard deviation.
Unless otherwise indicated, data represent No. (%) of subjects.
a Boldface P values indicate positive P values.
b Favorable IL-28 genotypes are in boldface type. Percentages of IL-28B genotype do not add up to 100% because of untypeable subjects in each cohort.